Swedish company Cantargia has enrolled the first patient in the Phase Ib/IIa trial of nadunolimab for treating individuals ...

TScan Therapeutics is developing TSC-101 and multiplex TCR-Ts for cancer treatment. See why TCRX stock holds potential with ...

Anaemia is defined as a reduction in haemoglobin levels, with thresholds of less than 12g/dL in women and less than 13g/dL in ...

Californian cell therapy company Orca Bio has announced positive results from the pivotal Phase III Precision-T study of d, its lead investigational allogeneic T-cell immunotherapy, acute myeloid ...

In a late-stage trial of patients with multiple types of blood cancer, Orca Bio’s allogeneic T-cell immunotherapy doubled the ...

Open label study in forty AML and MDS patients Study financed by the US Department of Defense Cantargia (Cantargia AB; Nasdaq ...

Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease ...

Keros Therapeutics' stock has plummeted over 70% due to safety issues in its phase 2 PAH study, halting all trial arms. Learn more about KROS stock here.

Despite a challenging year, FibroGen Inc (FGEN) focuses on promising drug developments and cost reductions to bolster future ...

A steam locomotive, which has been restored in memory of a boy from Plymstock, has made its maiden voyage. The 'Lord Oliver ...

Results showed Orca’s treatment, a purified mix of donor-derived T cells and stem cells, was safer than standard transplant ...

STATEN ISLAND, N.Y. — A fundraising Polar Plunge to honor John Hudson Dilgen will take place this month in South Beach to ...